451 related articles for article (PubMed ID: 29068242)
1. Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance.
Patlolla S; Vaikkakara S; Sachan A; Venkatanarasu A; Bachimanchi B; Bitla A; Settipalli S; Pathiputturu S; Sugali RN; Chiri S
Gynecol Endocrinol; 2018 Mar; 34(3):238-242. PubMed ID: 29068242
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
3. A Comparison of the Hormonal Profile of Early Androgenetic Alopecia in Men With the Phenotypic Equivalent of Polycystic Ovarian Syndrome in Women.
Sanke S; Chander R; Jain A; Garg T; Yadav P
JAMA Dermatol; 2016 Sep; 152(9):986-91. PubMed ID: 27304785
[TBL] [Abstract][Full Text] [Related]
4. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
[TBL] [Abstract][Full Text] [Related]
5. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome.
Cupisti S; Kajaia N; Dittrich R; Duezenli H; W Beckmann M; Mueller A
Eur J Endocrinol; 2008 May; 158(5):711-9. PubMed ID: 18426831
[TBL] [Abstract][Full Text] [Related]
6. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
[TBL] [Abstract][Full Text] [Related]
7. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
8. An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients.
Liao Y; Huang R; Sun Y; Yue J; Zheng J; Wang L; Tao T; Ma J; Li S; Liu W
Reprod Biol Endocrinol; 2017 Jan; 15(1):9. PubMed ID: 28125989
[TBL] [Abstract][Full Text] [Related]
9. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
[TBL] [Abstract][Full Text] [Related]
10. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.
Silfen ME; Denburg MR; Manibo AM; Lobo RA; Jaffe R; Ferin M; Levine LS; Oberfield SE
J Clin Endocrinol Metab; 2003 Oct; 88(10):4682-8. PubMed ID: 14557441
[TBL] [Abstract][Full Text] [Related]
11. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role?
Kauffman RP; Baker TE; Baker V; Kauffman MM; Castracane VD
Gynecol Endocrinol; 2010 Jan; 26(1):39-46. PubMed ID: 20001571
[TBL] [Abstract][Full Text] [Related]
12. [Clinical, hormonal and metabolic characteristics of different phenotypes of polycystic ovary syndrome, in Bulgarian population].
Kavardzhikova S; Pechlivanov B
Akush Ginekol (Sofiia); 2010; 49(4):32-7. PubMed ID: 20734639
[TBL] [Abstract][Full Text] [Related]
13. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents.
Li L; Chen X; He Z; Zhao X; Huang L; Yang D
J Pediatr Adolesc Gynecol; 2012 Dec; 25(6):390-5. PubMed ID: 23089573
[TBL] [Abstract][Full Text] [Related]
14. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
15. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
16. Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism.
Ezeh U; Ezeh C; Pisarska MD; Azziz R
Fertil Steril; 2021 Jun; 115(6):1557-1568. PubMed ID: 33602559
[TBL] [Abstract][Full Text] [Related]
17. Serum HLA-G levels in women with polycystic ovary syndrome.
Oztekin O; Fenkci SM; Fenkci V; Enli Y; Cabus U
Gynecol Endocrinol; 2015 Mar; 31(3):243-6. PubMed ID: 25403326
[TBL] [Abstract][Full Text] [Related]
18. Exploring the significance of sex hormone-binding globulin examination in the treament of women with polycystic ovarian syndrome (PCOS).
Lin XF; Wu RR; Du J; Liao YC; Du Y; Ye Y; Wang Y; Zhang XB; Wu C; Chen A
Clin Exp Obstet Gynecol; 2015; 42(3):315-20. PubMed ID: 26152001
[TBL] [Abstract][Full Text] [Related]
19. [Obesity, hormonal and metabolic abnormalities in adolescent girls with polycystic ovary syndrome].
Ságodi L; Lombay B; Vámosi I; Barkai L
Orv Hetil; 2013 Aug; 154(31):1226-34. PubMed ID: 23895991
[TBL] [Abstract][Full Text] [Related]
20. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome.
Alemzadeh R; Kichler J; Calhoun M
Eur J Endocrinol; 2010 Jun; 162(6):1093-9. PubMed ID: 20371657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
